Gill IS, et al. - Experts present the 4-year rates of a study with low-risk prostate cancer patients randomized in prospective trial PCM301 to partial gland ablation with vascular-targeted photodynamic therapy or active surveillance and further evaluate the effectiveness. The subsequent finding of higher-grade cancer on biopsy was significantly reduced by photodynamic therapy in this randomized trial of partial ablation vs surveillance for low-risk prostate cancer. Data demonstrated the conversion of fewer patients to radical therapy, a clinically meaningful benefit that lowers treatment-related morbidity.